湿性年龄相关性黄斑变性的治疗进展  

Recent advances in treatment of wet age-related macular degeneration

作　　者：栾兰[1] 姚勇[1] 

机构地区：[1]南京医科大学附属无锡市人民医院眼科,江苏省无锡市214023

出　　处：《眼科新进展》2013年第4期397-400,共4页Recent Advances in Ophthalmology

摘　　要：年龄相关性黄斑变性(age-related macular de-generation,AMD)是世界上50岁以上人群致盲眼病之一,其发病与多种因素有关。AMD在我国虽然不是主要致盲眼病,但却造成进行性、不可逆性视力损伤。随着人口老龄化,我国AMD的患病率也在增加,已经成为严重的公共卫生问题,尤其是湿性AMD。目前AMD的治疗包括物理治疗、药物治疗、手术治疗、基因治疗等,现就近年来AMD的治疗方法做一综述。Age-related macular degeneration（AMD）is one of diseases resulting in blindness which happens among people above 50 years old in the world,and its remote cause relates to many factors.Although AMD is not the leading cause of blindness in China yet,it leads to the progressive and irreversible visual impairment.With the aging rising,incidence of AMD in China has gradually increased,and AMD,especially wet AMD,has become a serious issue of public health.In recent years,there are a lot of treatments for AMD,such as physical therapy,drug treatment,surgery treatment,gene treatment,etc.This article reviews treatments of wet AMD.

关 键 词：年龄相关性黄斑变性 脉络膜新生血管 抗血管内皮生长因子 

分 类 号：R774.5[医药卫生—眼科]